Granules Pharmaceuticals, Inc

Granules Pharmaceuticals, Inc. is a U.S.-based pharmaceutical company specializing in the development and manufacturing of oral solid dosage forms, including tablets, capsules, and oral solutions. Established in 2014, the company operates as a wholly owned subsidiary of Granules India Limited, leveraging its parent company's extensive experience in the pharmaceutical industry. Headquartered in Chantilly, Virginia, Granules Pharmaceuticals, Inc. serves both the generic and branded pharmaceutical markets, focusing on providing high-quality and affordable healthcare solutions.

The company's facility in Chantilly is approved by the U.S. Food and Drug Administration (FDA) and the Drug Enforcement Administration (DEA), underscoring its commitment to regulatory compliance and quality standards. This facility supports both low and high-volume production, catering to a diverse range of pharmaceutical needs. Granules Pharmaceuticals, Inc. distributes its products under its own label, emphasizing cost-effectiveness and adherence to regulatory standards.

Granules Pharmaceuticals, Inc. operates a distribution network centered around its FDA and DEA-approved facility in Chantilly, Virginia. This facility serves as the primary hub for manufacturing and distributing the company's pharmaceutical products. While specific details about additional warehouse locations and logistics capabilities are not publicly disclosed, the Chantilly facility's approval by the FDA and DEA indicates a robust infrastructure capable of supporting both low and high-volume production.

Granules Pharmaceuticals, Inc. functions as a pharmaceutical manufacturer and distributor within the United States. By producing and supplying oral solid dosage forms, the company plays a significant role in the pharmaceutical supply chain, providing both generic and branded medications to the U.S. market. Its operations encompass the entire process from research and development to manufacturing and distribution, ensuring a steady supply of pharmaceutical products to meet market demands.

Granules Pharmaceuticals, Inc. imports finished pharmaceutical formulations exclusively from Granules India Limited, its parent company. This single-source dependency suggests a strategic choice to maintain control over product quality and supply chain efficiency. The substantial volume of imports—totaling $84.9 million across 1,739 shipments—indicates a stable and reliable relationship between the two entities. The concentration of imports in five therapeutic categories, with a focus on diabetes and endocrine products, reflects a targeted approach to meet specific market needs.

The resilience of Granules Pharmaceuticals, Inc.'s supply chain is closely tied to its exclusive reliance on Granules India Limited for finished pharmaceutical formulations. This centralized sourcing strategy may pose risks related to supply chain disruptions, such as production delays or regulatory challenges in India. However, the substantial volume of imports and the long-standing relationship between the two companies suggest a well-established and dependable supply chain. The focus on a limited number of therapeutic categories may also allow for more streamlined operations and quality control measures.

The sourcing pattern of Granules Pharmaceuticals, Inc. positions it to leverage the manufacturing capabilities and expertise of its parent company, Granules India Limited. This strategy enables the company to offer a focused portfolio of products, particularly in the diabetes and endocrine therapeutic areas, aligning with market demand for these medications. For Indian exporters seeking to become alternative suppliers, understanding the specific product categories and quality standards required by Granules Pharmaceuticals, Inc. is essential. Diversifying the product range and ensuring compliance with U.S. regulatory standards could enhance the attractiveness of Indian suppliers to the company.

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation and marketing of pharmaceutical products. The Federal Food, Drug, and Cosmetic Act (FD&C Act) provides the legal framework governing the importation of drugs, ensuring they meet standards for safety, efficacy, and quality. Pharmaceutical imports must comply with FDA regulations, including establishment registration, drug listing, and labeling requirements. The FDA also conducts inspections and enforces compliance to protect public health.

Importers of pharmaceutical products into the United States must adhere to specific licensing requirements. All foreign drug establishments whose products are imported are required to register with the FDA and list all their drug products in commercial distribution in the U.S. Additionally, imported drugs must be manufactured in compliance with Good Manufacturing Practice (GMP) standards. The FDA recognizes GMP certifications from various international bodies, including the European Union (EU) GMP, World Health Organization (WHO) GMP, and Pharmaceutical Inspection Co-operation Scheme (PIC/S). Importers must ensure that their products meet these standards to gain entry into the U.S. market.

Imported pharmaceutical products must comply with FDA labeling requirements, which include providing accurate and truthful information in English. The labeling must include the drug's name, ingredients, usage instructions, and any necessary warnings. Batch testing and stability studies are essential to ensure the product's safety and efficacy throughout its shelf life. Serialization mandates may apply to track and trace products through the supply chain, enhancing security and preventing counterfeit drugs. Compliance with these requirements is crucial for the admissibility of imported drugs into the U.S. market.

Between 2024 and 2026, the FDA has implemented several policy changes affecting pharmaceutical imports from India. These include enhanced scrutiny of manufacturing practices, stricter enforcement of labeling requirements, and increased inspections of foreign facilities. Importers must stay informed about these regulatory updates to ensure continued compliance and avoid potential disruptions in their supply chains. Engaging with the FDA's guidance and participating in industry forums can provide valuable insights into these changes.

Granules Pharmaceuticals, Inc. focuses on importing finished pharmaceutical formulations in the diabetes and endocrine therapeutic areas, accounting for 69.9% of its total imports. This strategic emphasis aligns with the high prevalence of diabetes in the United States and the growing demand for effective treatments. The company's portfolio also includes products in the nutritional supplements (12.3%) and CNS & psychiatric (9.1%) categories, reflecting a diversified approach to meet various market needs. By concentrating on these therapeutic areas, Granules Pharmaceuticals, Inc. aims to address significant health concerns and capitalize on market opportunities.

Granules Pharmaceuticals, Inc. employs a sourcing strategy that relies exclusively on its parent company, Granules India Limited, for finished pharmaceutical formulations. This approach ensures consistency in product quality and leverages the manufacturing expertise of Granules India Limited. The focus on a limited number of therapeutic categories allows for specialization and efficient supply chain management. While this strategy offers control over product quality and supply, it also necessitates careful management of the relationship with the sole supplier to mitigate potential risks associated with single-source dependency.

Granules Pharmaceuticals, Inc. serves the U.S. pharmaceutical market by providing both generic and branded medications, primarily focusing on oral solid dosage forms. Its product portfolio addresses significant health concerns, particularly in the diabetes and endocrine therapeutic areas, positioning the company to serve a broad segment of the market, including retail pharmacies, hospitals, and government tenders. By offering cost-effective and high-quality pharmaceutical solutions, Granules Pharmaceuticals, Inc. aims to meet the diverse needs of healthcare providers and patients across the United States.

For new Indian suppliers, there is a realistic opportunity to engage with Granules Pharmaceuticals, Inc. by understanding the company's specific product requirements and quality standards. Diversifying the product range to include therapeutic areas not currently covered by Granules Pharmaceuticals, Inc. could present a strategic advantage. Ensuring compliance with FDA regulations and obtaining necessary certifications, such as GMP approvals from recognized bodies, are essential steps for Indian exporters seeking to supply to the U.S. market. Building a strong relationship with Granules Pharmaceuticals, Inc. through transparent communication and consistent product quality can enhance the prospects of collaboration.

Indian exporters aiming to supply Granules Pharmaceuticals, Inc. and the broader U.S. market must adhere to specific certifications and quality standards. These include obtaining GMP certifications from recognized authorities such as the European Union (EU) GMP, World Health Organization (WHO) GMP, and Pharmaceutical Inspection Co-operation Scheme (PIC/S). Additionally, compliance with FDA regulations, including establishment registration, drug listing, and labeling requirements, is mandatory. Ensuring that products meet FDA standards for safety, efficacy, and quality is crucial for successful market entry.

To establish a relationship with Granules Pharmaceuticals, Inc., Indian exporters should begin by thoroughly understanding the company's product portfolio and identifying areas where their offerings can complement existing products.